Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two Medical Sciences Division scientists have been recognised in The Blavatnik Family Foundation and the New York Academy of Sciences Blavatnik Awards for Young Scientists, the largest unrestricted cash prizes available to scientists under the age of 42.

Eleanor Stride and Timothy Behrens

Professor Behrens and Professor Stride have been recognised in The Blavatnik Family Foundation and the New York Academy of Sciences Blavatnik Awards for Young Scientists, the largest unrestricted cash prizes available to scientists under the age of 42. 

Professor Timothy Behrens, from the Nuffield Department of Clinical Neuroscience (NDCN) at the University of Oxford receives a Laureateship worth £75,000 in the Life Sciences category. He has developed innovative models for mapping the brain's electrical signals that have significant implications for brain surgery, the treatment of mental disorders, and artificial intelligence.

Professor Eleanor Stride, from the Department of Engineering Science and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) at the University of Oxford, receives an award worth £23,000 as a Finalist. She is pioneering radical microbubble technology to develop more effective cancer treatments.

Read more about Timothy Behrens' research on the NDCN website

Read more about Eleanor Strides' research on the NDORMS website

Read the full story on University of Oxford website

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.